bioAffinity Technologies, Inc.
BIAF
$0.83
-$0.01-1.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -15.15% | 10.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.15% | 10.14% | |||
| Cost of Revenue | 3.17% | -4.47% | |||
| Gross Profit | -38.95% | 37.47% | |||
| SG&A Expenses | 6.73% | 37.47% | |||
| Depreciation & Amortization | -7.44% | 9.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.05% | 26.50% | |||
| Operating Income | -15.30% | -36.82% | |||
| Income Before Tax | -15.83% | 37.91% | |||
| Income Tax Expenses | -- | 0.00% | |||
| Earnings from Continuing Operations | -15.72% | 37.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.72% | 37.88% | |||
| EBIT | -15.30% | -36.82% | |||
| EBITDA | -16.23% | -38.26% | |||
| EPS Basic | -15.09% | 85.18% | |||
| Normalized Basic EPS | -15.20% | 85.19% | |||
| EPS Diluted | -15.09% | 85.18% | |||
| Normalized Diluted EPS | -15.20% | 85.19% | |||
| Average Basic Shares Outstanding | 0.54% | 319.21% | |||
| Average Diluted Shares Outstanding | 0.54% | 319.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||